Phyllis Kwok, MD
Internal Medicine · Bronxville, NYNPI 1629068671
Payments from drug & device makers
Across 251 payments — averaging $21.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$891
- Novo Nordisk$586
- Otsuka America Pharmaceutical, Inc.$529
- GSK$442
- Lundbeck LLC$404
- Lilly USA, LLC$375
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,341100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 37 | $891 |
| Novo Nordisk | 30 | $586 |
| Otsuka America Pharmaceutical, Inc. | 24 | $529 |
| GSK | 20 | $442 |
| Lundbeck LLC | 19 | $404 |
| Lilly USA, LLC | 17 | $375 |
| Pfizer | 17 | $325 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $183 |
| E.r. Squibb & Sons, L.L.C. | 9 | $181 |
| AstraZeneca | 7 | $155 |
| Amarin Pharma, Inc. | 7 | $132 |
| AbbVie | 4 | $113 |
| Kowa Pharmaceuticals America, Inc. | 8 | $112 |
| Intra-sana Laboratories | 3 | $99 |
| Merck | 5 | $92 |
| Zyla Life Sciences, Inc. | 4 | $82 |
| Exact Sciences | 3 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $57 |
| Scpharmaceuticals Inc. | 2 | $49 |
| Genentech USA, Inc. | 2 | $45 |
| Antares Pharma, Inc. | 2 | $42 |
| CSL Behring | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Organogenesis Inc. | 1 | $37 |
| Philips North America LLC | 1 | $27 |
| Dermira, Inc. | 1 | $25 |
| Amgen | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Medtronic | 1 | $19 |
| Circassia Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $9 |
How this compares
$5,341 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $57,457 |
| RexultiBrexpiprazole | 25 | $38,177 |
| JanuviaSitagliptin Phosphate | 29 | $27,717 |
| RybelsusSemaglutide | 12 | $27,204 |
| OzempicSemaglutide | 15 | $26,881 |
| JardianceEmpagliflozin | 19 | $19,880 |
| TrulicityDulaglutide | 13 | $18,227 |
| MounjaroTirzepatide | 17 | $16,450 |
| XareltoRivaroxaban | 12 | $10,396 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,566 |
| SynthroidLevothyroxine Sodium | 53 | $3,225 |
| Atorvastatin Calcium | 221 | $2,029 |
| Rosuvastatin Calcium | 144 | $1,886 |
| Levothyroxine Sodium | 137 | $1,333 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $325 | $57,45742 claims |
| Novo NordiskRybelsus, Ozempic | $586 | $54,08527 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $529 | $38,17725 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $375 | $34,67730 claims |
| MerckJanuvia | $92 | $27,71729 claims |
| Boehringer IngelheimJardiance | $891 | $19,88019 claims |
| GSKTrelegy Ellipta | $442 | $8,56613 claims |
| AbbVieSynthroid | $113 | $3,22553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronxville
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.